Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ketamine/sufentanil nasal spray - Cessatech

Next Previous
X
Search
Drug Profile

Ketamine/sufentanil nasal spray - Cessatech

Alternative Names: CT-001 Cessatech; Sufentanil/ketamine nasal spray - Cessatech

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cessatech
  • Class Amides; Analgesics; Antidepressants; Behavioural disorder therapies; Cyclohexanes; General anaesthetics; Opioid analgesics; Piperidines; Small molecules; Thiophenes
  • Mechanism of Action NMDA receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Procedural pain

Most Recent Events

  • 26 Aug 2024 Cessatech and Proveca enter an exclusive agreement for the commercialization of CT 001 world-wide excluding US
  • 27 May 2024 Phase-II/III clinical trials in Procedural pain (In infants, In children, In adolescents) in Spain (Intranasal) (NCT06364072)
  • 09 Jan 2024 Cessatech plans a phase II trial for Procedural pain in Spain and United Kingdom (Intranasal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top